33results about How to "Maintain effective plasma concentration" patented technology

The invention relates to a sustained release composition, and particularly relates to a water indissolvable/micro-dissolvable drug sustained release composition. The indissolvable/micro-dissolvable drug sustained release composition comprises more than two indissolvable/micro-dissolvable drug sustained release microspheres with different release behaviors. Through combining more than two drug sustained release microspheres with different release behaviors, the slow release composition of the indissolvable/micro-dissolvable drug is free from obvious release delay period or short delay release period, and also free from sudden release; the composition has good sustained release performance, and can maintain effective blood concentration within several weeks or above, thus the drug applying frequency is effectively reduced, the composition can facilitate patient's life and work; moreover, the composition is good for improving the drug applying compliance and convenience of the patient.

The invention relates to a slow-release tablet comprising succinate frovatriptan. The slow-release tablet comprises a tablet core and a coating, wherein the tablet core adopts a matrix tablet, and comprises succinate frovatriptan, hydroxypropyl methylcellulose, pregelatinized starch, magnesium stearate, talcum powder, and a 95% ethanol solution; the coating comprises a slow-release coating material, polyethylene glycol and succinate frovatriptan. The slow-release tablet has the advantages that the administration number of times is reduced, the compliance of a patient is improved, and the effective blood concentration is kept for a relatively long time.

The present invention relates to a docetaxel nanometer lipid injection. The invention also relates to a method for preparing the docetaxel nanometer lipid injection. The invention further relates to the application of the docetaxel nanometer lipid injection for preparing medicament for treating a tumor. The nanometer preparation of the invention is capable of prolonging the medicament action time, conveying the medicament with a target, reducing the administration dose under the precondition of ensuring the medicament action, alleviating or avoiding medicament toxin and side effects, improving the medicament action stability, and being benefited for the medicament storage, thus it is capable of implementing the development of the medicament which has advantages in the aspects of a high yield, automatization, large scale, low cost, convenient carry and storage, small dose and low side-effect.

The invention relates to an amoxicillin sustained release solid medicinal composition and a preparation method thereof. The composition which comprises a fast release unit containing amoxicillin, a first delayed release unit containing amoxicillin, and a second delayed release unit containing amoxicillin is characterized in that: the two delayed release units are a micropill or a particle which comprises a pill core containing amoxicillin, an inner pH-sensitive coating material which is coated on the inner layer of the pill core, and an outer hydrophilic coating material which is coated on the outer layer of the pill core, wherein pH-sensitive coating materials of the first delayed release unit and the second delayed release unit are different; the pH of the pH-sensitive release point of the coating materials of the first delayed release unit is equal to or more than 5.0; and the pH of the pH-sensitive release point of the coating materials of the second delayed release unit is equal to or more than 6.0. The composition allows the release degree of the tableted amoxicillin pH-sensitive coating micropill in the initial release stage to be improved.

Disclosed is a metronidazole double layer laminated slow release tablet comprising two layers, the first layer being a slow release layer consisting of metronidazole, slow release frame, binding agent and lubricating agent, the second layer being a quick release layer consisting of metronidazole, bulking agent, crumbling agent, binding agent and lubricating agent, wherein the mass ratio of metronidazole content in the slow release layer and in the quick release layer is 1 : 0.36-2.75. The invention also discloses the process for preparing the tablet.

The invention relates to a compound sustained-release preparation and a preparation method thereof, and the compound sustained-release preparation comprises Epristeride, terazosin hydrochloride and pharmaceutically acceptable auxiliary materials, wherein the Epristeride and the terazosin hydrochloride are used as the active components, the Epristeride is prepared into a sustained-release part, and the terazosin hydrochloride is prepared into an ordinary-release part, so that the two medicines are kept in an effective blood concentration range in vivo, the adverse effect of the medicines and the administration frequency are reduced, and the safety and effectiveness of pharmacy and the compliance of patients are improved.

The invention discloses a sustained-release tablet containing isradipine. The sustained-release tablet containing the isradipine is mainly prepared from the following raw materials in percentage by mass: 1-10% of isradipine, 20-60% of a framework material, 30-70% of a filler, 2-5% of an adhesive and 0.5-3% of a lubricant. The sustained-release tablet containing the isradipine can be used for treating hypertension. The sustained-release tablet containing the isradipine has the effects of sustained release of medicines, lasting medicine effect and stable blood concentration, has the advantages of reducing medicine administration times, improving medication compliance of patients, reducing adverse effects and improving the safety of medicine administration, and is more suitable for the patients; meanwhile, a preparation method of the sustained-release tablet containing the isradipine is simple in process and favorable for industrial mass production.

The invention relates to a sustained release preparation of blonanserin and a preparation method of the sustained release preparation of the blonanserin. A blonanserin tablet is prepared by mixing slow release particles prepared by slow release components and common components according to the prescription proportion; the mass ratio of the slow release components to the common components ranges from 75:25 to 80:20; the slow release components of the blonanserin tablet mainly comprise, by mass, 8.00%-12.0% of the blonanserin, 15.0%-20.0% of hydroxypropyl methylcellulose, 15.0%-25.0% of sodium carboxymethylcellulose and the like; the common components mainly comprise, by mass, 8.00%-12.0% of the blonanserin, 30.0%-50.0% of lactose and the like. By means of the tablet prepared from the sustained release preparation, the number of medicine taking can be decreased, the stable blood concentration can be maintained, and side effects can be reduced.

The invention relates to the technical field of medicines and provides a moxifloxacin hydrochloride medicine composition as well as a preparation method and application thereof. The moxifloxacin hydrochloride medicine composition comprises the following components in parts by weight: 40-50 parts of moxifloxacin hydrochloride, 4-5 parts of pregelatinized starch, 10-15 parts of microcrystalline cellulose, 3-4 parts of croscarmellose sodium and 0.3-1 part of magnesium stearate. The preparation method comprises the following steps: uniformly mixing the moxifloxacin hydrochloride, the pregelatinized starch, the microcrystalline cellulose and the croscarmellose sodium, adding water for pelletizing, further adding the magnesium stearate, and uniformly mixing, thereby obtaining capsules or tablets. According to the embodiment of the invention, contents of components are limited, medicines are slowly released in bodies; direct irritation of the moxifloxacin hydrochloride to gastrointestinal tracts can be alleviated; side effects, particularly serious gastrointestinal tract reactions, can be reduced; the compliance and the security of medicine taking can be improved for patients; patients can tolerate the composition; long-term treatment can be facilitated.

This invention supplies a Totelode osmosis pump type controlled release formulation, whose constitutes weight percentages are: Totelode 0.5-10.0 percent, findings for controlling release 80.0-99.0 percent and other findings. The type of this invention is osmosis pump troche. Findings for controlling release are separated to controlled release film material and controlled release osmotic pressure active compounds; the other findings contain bond, lubricant and thin film materials that usually used in troche preparation. This Totelode osmosis pump troche can keep effective medicine concentration for a day, advance curative effect and decrease side effect, and its release assumes zeroth-order characteristic in certain period. It is convenient to eat and taking, and it can cut down medicine-taking times. It can used broadly to cure urination frequent, urination urgent, precipitant urine incontinence, and so on caused by bladder pubovesical muscle excess excitation.

A percutaneous absorption type cerebral protective agent containing as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula: or a medically acceptable salt thereof in a base; a use of the compound as an active ingredient for the manufacture of a percutaneous absorption type pharmaceutical composition for protecting brain; and a method of protecting brain comprising administering to a patient the pharmaceutical composition as an active ingredient.

The invention discloses a technology for extracting phosphoesterase by ion exchange resin in the field of biological pharmacy. The phosphoesterase is prepared from the following ingredients in parts by weight: 3-35% of compound phosphoesterase, 20-55% of releasing agent and the balance of other medical ingredients. The preparation method for a sustained release tablet comprises the following steps that: preparing materials, pelletizing, carrying out size stabilization and tabletting. The sustained release tablet can realize a purpose that medicines can be slowly released in vivo for a long time, blood drug concentration is stable, and fluctuation is small so as to lower drug administration frequency and improve patient compliance. Through the control of the concentration of effective drug ingredients in blood, a drug effect can be conveniently maintained, a drug releasing peak receiving frequency is reduced, and certain protection is given to the visceral organs of a patient.

The invention relates to an oral medicine sustained-release preparation and a preparation method thereof, in particular relates to a skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet and a preparation method thereof, and belongs to the technical field of medicine. The skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet comprisesa skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pill core and a coating, wherein the sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet is prepared from sulfadiazine, sulfamethoxazole, trimethoprim, a diluent, adhesive, sodium carbonate, a skeleton material, a coating material and an anti-adhesion material according to a fluidized bed method.The sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet can fulfill the aims of reducing administration times, reducing the total dose of administration and increasing the recoveryrate through sustained release, and can optimize the clinical effect of sulfamethoxazole sulfadiazine and trimethoprim.

The invention discloses a preparation method of a medicine for treating hypertension. The method comprises the following steps: firstly mixing shell powder, organic microspheres and polyvinyl alcohol to prepare a green body; sintering the green body into solid and carrying out ball-milling to form powder to obtain a support material; carrying out sealed reaction on equimolar 1,4-butanolide and 6-caprolactone in presence of an alcohol initiator and an organic zinc catalyst in a nitrogen environment; terminating the reaction with glacial acetic acid, carrying out precipitating in ice diethyl ether, filtering and vacuum-drying to obtain a carbonic ester polymer; weighing an active medicine and the carbonic ester polymer, mixing evenly, adding the support material and a hydroxy propyl cellulose alcohol solution, pelletizing through a 30-mesh sieve and drying the product at 60 DEG C for 4 hours; and granulating through a 24-mesh sieve, mixing evenly, and tabletting to obtain the medicine for treating hypertension. According to the medicine, a few of components are fused into a whole through a splicing system to form a stable system, so that release of the medicine is relatively well controlled.

The invention provides an anti-inflammation analgesia medicine, particularly provides a diclofenac sodium sustained-release capsule and a production method thereof. The preparation method of the diclofenac sodium sustained-release capsule includes that diclofenac sodium is prepared to be a sustained-release pellet, and the sustained-release pellet is filled in the capsule. The diclofenac sodium sustained-release pellets is composed of a blank pellet core serving as a parent nucleus, a main medicine layer and a sustained-release coating layer, the main medicine layer contains the diclofenac sodium and is coated outside the pellet core, and the sustained-release coating layer is coated outside the main medicine layer. The diclofenac sodium sustained-release capsule has the advantages that the preparation stability is good, the releasing effect is remarkably excellent, and compared with common capsules, the diclofenac sodium sustained-release capsule is safe and convenient for a patient to take in.